Edgar Castillo
Psychiatry · Fresno, CANPI 1851492847
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 622 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 622 payments — averaging $28.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$2K
- Alkermes, Inc.$2K
- Vanda Pharmaceuticals Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- plus $6K from 17 others
What the payments were for
- Consulting fees$2001%
- Food & beverage$17,03497%
- Education$3112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 109 | $3,459 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 83 | $2,165 |
| AbbVie(2 entities) | 89 | $1,873 |
| Alkermes, Inc. | 59 | $1,727 |
| Vanda Pharmaceuticals Inc. | 48 | $1,324 |
| Teva Pharmaceuticals USA, Inc. | 44 | $1,216 |
| Takeda Pharmaceuticals U.S.A., Inc. | 52 | $793 |
| Johnson & Johnson | 20 | $783 |
| Axsome Therapeutics, Inc. | 18 | $762 |
| Neurocrine Biosciences, Inc. | 12 | $698 |
| Lundbeck LLC | 27 | $546 |
| E.r. Squibb & Sons, L.L.C. | 13 | $509 |
| Sunovion Pharmaceuticals Inc. | 24 | $467 |
| Ironshore Pharmaceuticals Inc. | 2 | $244 |
| Supernus Pharmaceuticals, Inc. | 8 | $219 |
| Janssen Scientific Affairs, LLC | 1 | $200 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $166 |
| Avanir Pharmaceuticals, Inc. | 1 | $125 |
| Boehringer Ingelheim | 1 | $121 |
| Indivior Inc. | 4 | $71 |
| Shire North American Group Inc | 3 | $43 |
| Novo Nordisk | 1 | $22 |
| Adlon Therapeutics L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,480
- REXULTI$1,312
- CAPLYTA$1,192
- ABILIFY MAINTENA$971
- ARISTADA$964
- INGREZZA$639
- Fanapt$625
- SPRAVATO$446
- Auvelity$370
- ABILIFY ASIMTUFII$369
- VRAYLAR$360
- COBENFY$248
- Jornay PM 20mg capsules (Bottle of 100)$244
- ARISTADA INITIO$241
- INVEGA SUSTENNA$231
- INVEGA TRINZA$231
- UZEDY$125
- NUEDEXTA$125
- AUSTEDO$125
- QELBREE$125
How this compares
$17,545 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 73 | $50,706 |
| VraylarCariprazine Hcl | 19 | $27,461 |
| TrintellixVortioxetine Hydrobromide | 45 | $14,650 |
| Ziprasidone Hcl | 23 | $966 |
| Buspirone Hcl | 41 | $807 |
| Mirtazapine | 39 | $291 |
| Sertraline Hcl | 35 | $167 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $154 |
| Hydroxyzine Hcl | 13 | $146 |
| Aripiprazole | 16 | $140 |
| Olanzapine | 11 | $126 |
| Trazodone Hcl | 13 | $101 |
| Lorazepam | 13 | $69 |
| Zolpidem Tartrate | 15 | $55 |
| Clonazepam | 15 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $3,459 | $50,70673 claims |
| AbbVieVraylar | $1,873 | $27,46119 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $793 | $14,65045 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Fresno
- Herbert CruzFresno$394K
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.